T3+ and T4 rectal cancer patients seem to benefit from the addition of oxaliplatin to the neoadjuvant chemoradiation regimen.
Martijnse IS, Dudink RL, Kusters M, Vermeer TA, West NP, Nieuwenhuijzen GA, van Lijnschoten I, Martijn H, Creemers GJ, Lemmens VE, van de Velde CJ, Sebag-Montefiore D, Glynne-Jones R, Quirke P, Rutten HJ.
Martijnse IS, et al. Among authors: dudink rl.
Ann Surg Oncol. 2012 Feb;19(2):392-401. doi: 10.1245/s10434-011-1955-1. Epub 2011 Jul 27.
Ann Surg Oncol. 2012.
PMID: 21792506
Clinical Trial.